MCHP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Microchip Technology Inc (MCHP) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock shows some positive technical trends and moderate growth potential, the overbought RSI, insider selling, and mixed analyst ratings suggest caution. Additionally, the company's recent financial performance, particularly the significant drop in net income and EPS, raises concerns about its profitability. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on investing in MCHP at this time is advisable.
The technical indicators show a bullish trend with MACD positively expanding and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, the RSI is at 98.102, indicating the stock is overbought, which could lead to a short-term pullback. The stock is trading near its resistance level of 93.728, which may act as a barrier to further price increases.
Recent launch of low-power MCUs aimed at industrial and automotive applications, which could drive future growth.
Positive sentiment in the analog chip market, as indicated by strong forecasts from Texas Instruments.
Improving demand environment as reflected in Q4 guidance above expectations.
Insider selling has increased significantly (4258.22% over the last month), indicating potential lack of confidence from insiders.
Analysts have mixed ratings, with some lowering price targets and highlighting risks such as potential loss of market share in microcontrollers.
Financial performance shows a significant drop in net income (-165.11% YoY) and EPS (-160.00% YoY), raising concerns about profitability.
In Q3 2026, revenue increased by 15.59% YoY to $1.186 billion, and gross margin improved by 18.14% YoY to 50.53%. However, net income dropped by -165.11% YoY to $34.9 million, and EPS fell by -160.00% YoY to $0.06, indicating profitability challenges.
Analyst ratings are mixed. Barclays initiated coverage with an Equal Weight rating and a $80 price target, citing risks of losing market share. Truist raised its price target to $69 but maintained a Hold rating. On the positive side, Needham, Mizuho, Evercore ISI, and JPMorgan raised their price targets to $84, $90, $93, and $95 respectively, with some maintaining Buy or Outperform ratings. However, there are concerns about the company's ability to sustain growth in a competitive market.
